Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 + dabrafenib + trametinib vs placebo + dabrafenib + trametinib in untreated unresectable or metastatic BRAF V600 mutant melanoma
2016-002794-35Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2016
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing PDR001 + dabrafenib + trametinib with Placebo + dabrafenib + trametinib (2 arms). Primary endpoint: Incidence of dose limiting toxicities (DLTs). Started Nov 2016; status: completed.
02
Drugs
spartalizumabdabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2016-002794-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002794-35.